Ata uhi

Pharmacological Characterization of Toludesvenlafaxine as a Triple Reuptake Inhibitor

Toludesvenlafaxine hydrochloride dihydrate is a novel chemical entity and a potential triple monoamine reuptake inhibitor. This study characterized the in vitro triple reuptake inhibition activity, antidepressant-like activity in animals, and pharmacokinetic profiles in rats of toludesvenlafaxine. B...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Haibo Zhu (Author), Wenyan Wang (Author), Chunjie Sha (Author), Wei Guo (Author), Chunmei Li (Author), Fengjuan Zhao (Author), Hongbo Wang (Author), Wanglin Jiang (Author), Jingwei Tian (Author)
Hōputu:	Pukapuka
I whakaputaina:	Frontiers Media S.A., 2021-09-01T00:00:00Z.
Ngā marau:	article
Urunga tuihono:	Connect to this object online.
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite

The effect of triple reuptake inhibitor toludesvenlafaxine on neurological function in cerebral ischemic rats
mā: Xiaohui Sun, me ētahi atu.
I whakaputaina: (2023)

LPM580098, a Novel Triple Reuptake Inhibitor of Serotonin, Noradrenaline, and Dopamine, Attenuates Neuropathic Pain
mā: Nannan Li, me ētahi atu.
I whakaputaina: (2019)

Epigenetic Mechanism of 5-HT/NE/DA Triple Reuptake Inhibitor on Adult Depression Susceptibility in Early Stress Mice
mā: Ping Meng, me ētahi atu.
I whakaputaina: (2022)

Subacute toxicity evaluations of LPM3480392 in rats, a full µ-opioid receptor biased agonist
mā: Liang Ye, me ētahi atu.
I whakaputaina: (2023)

PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression in vitro and in vivo
mā: Fangfang Li, me ētahi atu.
I whakaputaina: (2020)

LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer
mā: Jiahao Qiu, me ētahi atu.
I whakaputaina: (2022)

Monoaminergic Antidepressants in the Relief of Pain: Potential Therapeutic Utility of Triple Reuptake Inhibitors (TRIs)
mā: Bruno P. Guiard, me ētahi atu.
I whakaputaina: (2011)

Pharmacological and toxicological studies of a novel goserelin acetate extended-release microspheres in rats
mā: Mao Yutong, me ētahi atu.
I whakaputaina: (2023)

Sentiment Analysis of Online Reviews for Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors
mā: Chad Compagner, me ētahi atu.
I whakaputaina: (2021)

Decreased Growth with Serotonin Reuptake Inhibitors
mā: J Gordon Millichap
I whakaputaina: (2002)

Efficacy, Tolerability, and Safety of Toludesvenlafaxine for the Treatment of Major Depressive Disorder-A Narrative Review
mā: Octavian Vasiliu
I whakaputaina: (2023)

(+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia
mā: Wenyan Wang, me ētahi atu.
I whakaputaina: (2021)

Suicide attempt with selective serotonin reuptake inhibitor antidepressants
mā: Sandra Cuenca Carcelén, me ētahi atu.
I whakaputaina: (2021)

PCC0208057 as a small molecule inhibitor of TRPC6 in the treatment of prostate cancer
mā: Yingjie Wei, me ētahi atu.
I whakaputaina: (2024)

Anti-Colorectal Cancer Effects of a Novel Camptothecin Derivative PCC0208037 <i>In Vitro</i> and <i>In Vivo</i>
mā: Min Li, me ētahi atu.
I whakaputaina: (2022)

Selective Serotonin Reuptake Inhibitors in Human Pregnancy: To Treat or Not to Treat?
mā: Orna Diav-Citrin, me ētahi atu.
I whakaputaina: (2012)

Prenatal exposure to serotonin reuptake inhibitors: a case report
mā: Solinas Agostina, me ētahi atu.
I whakaputaina: (2010)

Selective Serotonin Reuptake Inhibitor Pharmaco-Omics: Mechanisms and Prediction
mā: Thanh Thanh L. Nguyen, me ētahi atu.
I whakaputaina: (2021)

Serotonin reuptake inhibitors and post-gastrostomy bleeding: reevaluating the link
mā: Patel H, me ētahi atu.
I whakaputaina: (2015)

Pediatric Therapeutic Drug Monitoring for Selective Serotonin Reuptake Inhibitors
mā: Jeffrey R. Strawn, me ētahi atu.
I whakaputaina: (2021)

New Serotonin-Norepinephrine Reuptake Inhibitors and Their Anesthetic and Analgesic Considerations
mā: David Fanelli, me ētahi atu.
I whakaputaina: (2021)

A small-molecule inhibitor of MDMX suppresses cervical cancer cells via the inhibition of E6-E6AP-p53 axis
mā: Jingwen Zhang, me ētahi atu.
I whakaputaina: (2022)

Biological evaluation and in silico studies of novel compounds as potent TAAR1 agonists that could be used in schizophrenia treatment
mā: Yunjie Wang, me ētahi atu.
I whakaputaina: (2023)

A Bibliometric Analysis of the WoSCC Literature on the Use of Selective Serotonin Reuptake Inhibitors as Antidepressants
mā: Li J, me ētahi atu.
I whakaputaina: (2024)

The Effects of Selective Serotonin-Reuptake Inhibitor on Visual Evoked Potential in Rats
mā: Yoshihiro Iwamura, me ētahi atu.
I whakaputaina: (2004)

Experimental Dopamine Reuptake Inhibitors in Parkinson’s Disease: A Review of the Evidence
mā: Müller T
I whakaputaina: (2021)

Selective Serotonin Reuptake Inhibitors and Clozapine: Clinically Relevant Interactions and Considerations
mā: Amber N. Edinoff, me ētahi atu.
I whakaputaina: (2021)

Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review
mā: Amber N. Edinoff, me ētahi atu.
I whakaputaina: (2021)

Selective Serotonin Reuptake Inhibitor Pharmacokinetics During Pregnancy: Clinical and Research Implications
mā: Ethan A. Poweleit, me ētahi atu.
I whakaputaina: (2022)

Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19
mā: Mahsa Asadi Anar, me ētahi atu.
I whakaputaina: (2022)

Can a Selective Serotonin Reuptake Inhibitor Act as a Glutamatergic Modulator?
mā: Marcos Emilio Frizzo, PhD
I whakaputaina: (2017)

Selective serotonin reuptake inhibitors suppress sharp wave ripples in the ventral hippocampus
mā: Hiromi Shiozaki, me ētahi atu.
I whakaputaina: (2023)

Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis
mā: Wang Z, me ētahi atu.
I whakaputaina: (2022)

Selective serotonin reuptake inhibitors and suicidality in children and young adults: analyses of pharmacovigilance databases
mā: Diana Dubrall, me ētahi atu.
I whakaputaina: (2023)

The Effect of Serotonin-Norepinephrine Reuptake Inhibitor Milnacipran on Anxiety-like Behaviors in Diabetic Mice
mā: Tuhfatul Ulya, me ētahi atu.
I whakaputaina: (2021)

Role of selective serotonin reuptake inhibitors in prognosis dental implants: A retrospective study
mā: Praveen Chandra, me ētahi atu.
I whakaputaina: (2021)

Combining fecal microbiome and metabolomics to reveal the disturbance of gut microbiota in liver injury and the therapeutic mechanism of shaoyao gancao decoction
mā: Jingwei Li, me ētahi atu.
I whakaputaina: (2022)

Secondary and side effects of particular Selective Serotonin Reuptake Inhibitors (SSRIs) antidepressants - literature review
mā: Ewa Krzewicka-Romaniuk, me ētahi atu.
I whakaputaina: (2020)

Differentiated HT22 cells as a novel model for in vitro screening of serotonin reuptake inhibitors
mā: Juhee Lim, me ētahi atu.
I whakaputaina: (2023)

Exploring the Relationship Between Neighborhood-Built Environment and Elderly Health: A Research Based on Heterogeneity of Age and Gender Groups in Beijing
mā: Jingwei Li, me ētahi atu.
I whakaputaina: (2022)